[
    [
        {
            "time": "",
            "original_text": "贝达药业(300558)2020年业绩预告点评：扣非业绩高速增长 埃克替尼有望稳步增长",
            "features": {
                "keywords": [
                    "贝达药业",
                    "业绩预告",
                    "扣非业绩",
                    "埃克替尼",
                    "高速增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558)2020年业绩预告点评：扣非业绩高速增长 埃克替尼有望稳步增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "“抗癌第一股”贝达药业准备赴港上市！它会复制泰格医药的走势吗？",
            "features": {
                "keywords": [
                    "贝达药业",
                    "赴港上市",
                    "泰格医药",
                    "走势"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "“抗癌第一股”贝达药业准备赴港上市！它会复制泰格医药的走势吗？",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558)：业绩大超预期 恩沙替尼开始贡献收入 Q4表现亮眼",
            "features": {
                "keywords": [
                    "贝达药业",
                    "业绩大超预期",
                    "恩沙替尼",
                    "Q4表现亮眼"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558)：业绩大超预期 恩沙替尼开始贡献收入 Q4表现亮眼",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "贝达药业预计2020年度归母净利润5.89亿-6.58亿 同比增逾1.5倍",
            "features": {
                "keywords": [
                    "贝达药业",
                    "归母净利润",
                    "同比增长",
                    "1.5倍"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业预计2020年度归母净利润5.89亿-6.58亿 同比增逾1.5倍",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "中泰证券--医药生物行业周报：CRO/CDMO行情将如何延续？长坡厚雪，未来可期【行业研究】",
            "features": {
                "keywords": [
                    "中泰证券",
                    "医药生物",
                    "CRO/CDMO",
                    "行情延续",
                    "长坡厚雪"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中泰证券--医药生物行业周报：CRO/CDMO行情将如何延续？长坡厚雪，未来可期【行业研究】",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]